logo

Biotech Stocks Facing FDA Decision In February 2020

22nd Century Group
22nd Century Group

22nd Century Group Inc.’s (XXII) Modified Risk Tobacco Product (MRTP) application for its very low nicotine content cigarettes under the proposed brand name of VLN cigarettes is slated to be reviewed by the FDA’s Tobacco Products Scientific Advisory Committee on February 14, 2020.

The Company’s MRTP application seeks FDA to authorize the marketing of VLN with the assertion that they contain 95% less nicotine than conventional tobacco cigarettes, as well as other related claims.
The Tobacco Products Scientific Advisory Committee meeting is a required step in the FDA’s review of the Company’s request to commercialize VLN cigarettes in the United States as a “Modified Risk Tobacco Product”.

XXII closed Monday’s trading at $1.05, down 0.94%.

Share